Status:
COMPLETED
Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)
Lead Sponsor:
Bronx VA Medical Center
Conditions:
Hypercholesterolemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to compare the effect on LDL cholesterol levels of converting patients who are receiving the cholesterol absorption inhibitor Zetia at a dose of 10 milligrams to 5 milligr...
Eligibility Criteria
Inclusion
- Subjects receiving ezetimibe 10 mg
- Subjects who have demonstrated compliance with ezetimibe as evidenced by the following Proportions of Days Covered patterns (which represent a PDC of more than 75%):
- 90 day prescriptions: Filled a ezetimibe prescription within the previous 4 months
- 60 day prescriptions: Filled a ezetimibe prescription within the previous 2.5 months
- 30 day prescriptions: Filled a ezetimibe prescription within the previous 1.5 months
- Patients willing and able to provide signed informed consent
Exclusion
- Patients not receiving ezetimibe
- Patients receiving ezetimibe 5 milligrams
- Patients with a history of being titrated from ezetimibe 5 to 10 mg. Stroke,TIA, myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass surgery, or major surgery within the 3 months
- Cancer undergoing active treatment
- Participation in any clinical study within the last 30 days
- Drug addiction or alcohol abuse within the past 6 months
- Patients unwilling or unable to provide informed consent
- Patients with poor compliance
- Women of childbearing potential
Key Trial Info
Start Date :
July 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00762229
Start Date
July 1 2007
End Date
September 1 2008
Last Update
June 14 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bronx VA Medical Center
The Bronx, New York, United States, 10468